Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taisho Buys Biofermin In All-Japanese Acquisition

This article was originally published in PharmAsia News

Executive Summary

Japan's Taisho Pharmaceutical has bought a controlling interest in Biofermin Pharmaceutical for $240.2 million. The Taisho purchase amounts to a 54.8 percent stake in Biofermin, which Taisho plans to make a subsidiary. Biofermin has a marketing agreement with Takeda Pharmaceutical, which opposed the Taisho bid, but that contract is to remain in place. The acquiring company plans to develop lactobacillus products, using Biofermin facilities. (Click here for more - may require a subscription

You may also be interested in...



Coronavirus Update: Gilead's Veklury Gets Full FDA Approval, Roche Partners With Atea

Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine. 

US COVID-19 Vaccine Adcomm: First Take-Aways

From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.

QUOTED. 23 October. Dan Buehner.

Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel